Skip to main content

CORRECTION article

Front. Med., 10 October 2022
Sec. Nephrology
This article is part of the Research Topic Advances in the Diagnosis and Treatment in Kidney Transplantation, Volume II View all 19 articles

Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial

  • 1Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
  • 2Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  • 3Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

A corrigendum on
Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial

by Heinzel, A., Schrezenmeier, E., Regele, F., Hu, K., Raab, L., Eder, M., Aigner, C., Jabbour, R., Aschauer, C., Stefanski, A.-L., Dörner, T., Budde, K., Reindl-Schwaighofer, R., and Oberbauer, R. (2022). Front. Med. 9:936126. doi: 10.3389/fmed.2022.936126

In the published article, an author name was incorrectly written as “Schretzenmeier.”

The correct spelling is “Schrezenmeier.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: COVID-19, kidney transplantation, COVID-19 vaccination, heterologous vaccination, third vaccination

Citation: Heinzel A, Schrezenmeier E, Regele F, Hu K, Raab L, Eder M, Aigner C, Jabbour R, Aschauer C, Stefanski A-L, Dörner T, Budde K, Reindl-Schwaighofer R and Oberbauer R (2022) Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial. Front. Med. 9:1048395. doi: 10.3389/fmed.2022.1048395

Received: 19 September 2022; Accepted: 20 September 2022;
Published: 10 October 2022.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Heinzel, Schrezenmeier, Regele, Hu, Raab, Eder, Aigner, Jabbour, Aschauer, Stefanski, Dörner, Budde, Reindl-Schwaighofer and Oberbauer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Roman Reindl-Schwaighofer, roman.reindl-schwaighofer@meduniwien.ac.at

These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.